Soleus Capital Management L.P. Sells 50,000 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Soleus Capital Management L.P. decreased its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 12.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 349,982 shares of the company’s stock after selling 50,000 shares during the quarter. Soleus Capital Management L.P.’s holdings in Y-mAbs Therapeutics were worth $2,740,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in YMAB. Principal Financial Group Inc. raised its holdings in Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock worth $174,000 after purchasing an additional 1,903 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Y-mAbs Therapeutics by 12.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company’s stock valued at $179,000 after buying an additional 2,545 shares during the period. JPMorgan Chase & Co. increased its position in shares of Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after buying an additional 2,854 shares during the period. SG Americas Securities LLC raised its stake in Y-mAbs Therapeutics by 30.7% in the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after buying an additional 4,163 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Y-mAbs Therapeutics by 1.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock worth $2,228,000 after buying an additional 4,963 shares during the period. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Performance

NASDAQ:YMAB opened at $4.10 on Monday. The firm has a market cap of $185.66 million, a P/E ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $16.11. The firm has a 50-day simple moving average of $4.47 and a two-hundred day simple moving average of $7.00.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $20.90 million during the quarter, compared to the consensus estimate of $19.97 million. On average, equities research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares in the company, valued at $1,060,230.83. The trade was a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 22.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on YMAB. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Morgan Stanley lowered their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday, March 5th. HC Wainwright reduced their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Truist Financial dropped their price objective on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, Bank of America downgraded shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a research note on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.70.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.